Last reviewed · How we verify
NCT03382106
Smoking Cessation and Functional CT Assessment
Phase 4 trial testing Sildenafil 20 MG in Emphysema in 162 participants. Completed in 24 September 2024.
24 September 2024
Quick facts
| Lead sponsor | Eric A. Hoffman |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 162 |
| Start date | 19 March 2018 |
| Primary completion | 24 September 2024 |
| Estimated completion | 24 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sildenafil 20 MG — full drug profile →
- Placebo Oral Tablet — full drug profile →
- Pulse wave velocity
- Carotid artery compliance and stiffness
- Pressure wave reflection
Conditions studied
- Emphysema — all drugs for Emphysema →
Sponsor
Eric A. Hoffman — full company profile →
Who can join
Adults 21 to 65, any sex, with Emphysema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03382106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sildenafil 20 MG
Trials testing the same drug.
- NCT04908657 — Sildenafil for Liver Fibrosis in Adolescents and Adults After Fontan Operation · Phase 4 · unknown
- NCT03262961 — Use of Sildenafil Citrate in Management of Mild Pre-eclampsia · Phase 2, PHASE3 · unknown
Other recruiting trials for Emphysema
Currently open trials in the same condition.
- NCT07059637 — Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD · NA · recruiting
- NCT06891755 — Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 · NA · recruiting
- NCT06025500 — Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment · recruiting
- NCT06533371 — Clinical-ultrasonographic Assessment of Pulmonary Emphysema · NA · recruiting
- NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting
Other Eric A. Hoffman trials
Trials by the same sponsor.
- NCT03733470 — Hypoxic Pulmonary Vasoconstriction Pilot Study · Phase 4 · completed
- NCT03764163 — Image and Model Based Analysis of Lung Disease · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03382106 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eric A. Hoffman
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03382106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing